Breaking News Instant updates and real-time market news.

INCY

Incyte

$133.42

0.2 (0.15%)

, GILD

Gilead

$70.58

0.78 (1.12%)

07:15
07/14/17
07/14
07:15
07/14/17
07:15

Acquisition of Incyte would make sense for Gilead, says Leerink

Leerink analyst Geoffrey Porges, who noted he has "written extensively about the imperative for Gilead to diversify their portfolio and secure additional pipeline programs," said in a new note to investors that he believes an acquisition of Incyte (INCY) would make sense for Gilead (GILD). At a "reasonable acquisition premium," Gilead could pay $173-$187 per share for Incyte and its earnings would be diluted through 2018, but thereafter would be increased by such a deal, estimated Porges. The analyst, who concluded that Incyte presents a high-risk/high-reward option for Gilead, keeps a Market perform rating on Gilead shares.

INCY

Incyte

$133.42

0.2 (0.15%)

GILD

Gilead

$70.58

0.78 (1.12%)

  • 26

    Jul

  • 01

    Aug

INCY Incyte
$133.42

0.2 (0.15%)

06/06/17
BMOC
06/06/17
NO CHANGE
BMOC
Incyte should be bought on recent weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that data on the combination of Bristol-Myers' (BMY) Opdivo and Incyte's (INCY) epacadostat "confirmed the benefit" seen in a previous study. The analyst says that the safety of Merck's (MRK) Keytruda in combination with epacadostat is better than the standard of care. He keeps a $166 price target and Outperform rating on Incyte.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Credit Suisse sees no impact to Incyte's epacadostat from NewLink IDO news
Credit Suisse analyst Alethia Young said she is not surprised that Roche (RHHBY) returned IDO inhibitor GDC-0919 to NewLink (NLNK) after seeing the "disappointing data" at ASCO. She doesn't see an impact to Incyte's (INCY) own IDO inhibitor, epacadostat, from the news, as she thought the data made GDC-0919 appear clinically inferior to epacadostat in combination with PD-1. She keeps an Outperform rating on Incyte shares, adding that investors may get another update on Bristol-Myers' (BMY) internal IDO, BMS-986205, later this year.
06/12/17
LEER
06/12/17
NO CHANGE
Target $90
LEER
Outperform
Eli Lilly price target lowered to $90 from $93 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Eli Lilly (LLY) to $90 to reflect reduced sales forecasts for baricitinib, an oral JAK1/2 inhibitor to treat rheumatoid arthritis which the company collaborates with Incyte (INCY). Following AbbVie's (ABBV) positive Phase 3 data last week for its JAK1 inhibitor upadacitinib, Fernandez dropped his U.S. peak sales estimate for baricitinib by more than 50% to $400M and pushed out his U.S. launch time to 2020 from 2018. The analyst keeps an Outperform rating on Lilly shares.
07/12/17
OPCO
07/12/17
NO CHANGE
OPCO
Incyte could see a 9% increment in value, says Oppenheimer
Oppenheimer analyst Jay Olson says Incyte's shares could see a 9% increment in value if the July 25 pipeline update on Olumiant is favorable pointing to a resubmission post-CRL without any new clinical trials required. Separately, Incyte's valuation could reduce by around 11% in the analyst's worst case scenario if read across from MYSTIC is negative based on a positive result for the PD-L1 plus CTLA-4 combo versus chemo in 1L NSCLC all comers.
GILD Gilead
$70.58

0.78 (1.12%)

07/03/17
COWN
07/03/17
NO CHANGE
Target $90
COWN
Outperform
Gilead raised prices on several drugs by 6.9%, says Cowen
Third party sources indicate that Gilead Sciences increased the U.S. prices of several products by 6.9%, Cowen analyst Phil Nadeau tells investors in a research note. The analyst notes the increases are consistent with Gilead's historical practice, which is to raise the prices of most of its medicines once per year. Nadeau adds that Genvoya's discount to Stribild was restored to 11%, which he believes should help maintain the momentum of Genvoya's launch. The analyst maintains an Outperform rating on Gilead.
07/05/17
SBSH
07/05/17
NO CHANGE
Target $65
SBSH
Neutral
Merck could become market leader in HIV, says Citi
In a research note titled "EFdA - The Remarkable HIV Drug That Could End GILD/ViiV's Dominance," Citi analyst Andrew Baum says he finds it likely that Merck (MRK) could become a market leader in HIV treatment. Given EFdA's profile, Merck intends to develop an oral daily single tablet coformulated with Isentress HD or another oral antiretroviral for HIV-infected patients, Baum tells investors in a research note. He models first EFdA approval as early as 2021 and believes commercial success could add $5B per year to sales forecasts. The analyst keeps a Neutral rating on Merck with a $65 price target.
07/10/17
JEFF
07/10/17
INITIATION
Target $80
JEFF
Gilead assumed with a Hold at Jefferies
Jefferies analyst Michael Yee assumed coverage on Gilead with a Hold and an $80 price target.
07/13/17
BARD
07/13/17
NO CHANGE
Target $87
BARD
Outperform
Baird likes Gilead heading into Q2 earnings
Baird analyst Brian Skorney said he likes Gilead heading into Q2 earnings. The analyst said Hep-C sales should beat estimates and predicts its sales decline should be approaching a plateau, which would result in upside to the shares. He said the operating results could provide much needed stability, which should also result in upside. Skorney maintained his Outperform rating and $87 price target on Gilead shares.

TODAY'S FREE FLY STORIES

TWX

Time Warner

$101.83

-0.37 (-0.36%)

, CMCSA

Comcast

$37.22

0.32 (0.87%)

18:56
10/22/17
10/22
18:56
10/22/17
18:56
Hot Stocks
Box Office Battle: 'Boo 2' wins weekend with $21.7M »

Lionsgate's (LGF.A)…

TWX

Time Warner

$101.83

-0.37 (-0.36%)

CMCSA

Comcast

$37.22

0.32 (0.87%)

CMCSK

Comcast

SNE

Sony

$37.55

0.11 (0.29%)

FOX

21st Century Fox

$26.84

0.14 (0.52%)

FOXA

21st Century Fox

$27.50

0.13 (0.47%)

LGF.A

Lionsgate

$30.09

-0.08 (-0.27%)

DIS

Disney

$99.40

0.39 (0.39%)

VIAB

Viacom

$26.70

0.17 (0.64%)

VIA

Viacom

$34.00

-0.05 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

  • 08

    Nov

  • 09

    Nov

  • 09

    Nov

  • 16

    Nov

SFNC

Simmons First National

$60.45

0.9 (1.51%)

18:16
10/22/17
10/22
18:16
10/22/17
18:16
Earnings
Simmons First National reports Q3 core EPS 86c, consensus 86c »

Reports Q3 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HLX

Helix Energy

$7.76

-0.13 (-1.65%)

18:09
10/22/17
10/22
18:09
10/22/17
18:09
Earnings
Helix Energy reports Q3 EPS 2c, consensus 2c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GM

General Motors

$45.61

0.26 (0.57%)

18:00
10/22/17
10/22
18:00
10/22/17
18:00
Periodicals
Driverless-car, emerging tech bets help GM shrug off 'dinosaur' image, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GOOG

Alphabet

$988.20

3.75 (0.38%)

, GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

17:42
10/22/17
10/22
17:42
10/22/17
17:42
Periodicals
Alphabet turns on internet balloons in Puerto Rico, AP says »

Alphabet's…

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

AAPL

Apple

$156.25

0.27 (0.17%)

, AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

17:30
10/22/17
10/22
17:30
10/22/17
17:30
Periodicals
Facebook, Google spending big money to lobby on Russia, Recode says »

Apple (AAPL), Amazon…

AAPL

Apple

$156.25

0.27 (0.17%)

AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

FB

Facebook

$174.98

0.42 (0.24%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

MSFT

Microsoft

$78.81

0.9 (1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 01

    Nov

  • 02

    Nov

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

XBKS

Xenith Bankshares

$32.74

-0.1 (-0.30%)

, UBSH

Union Bankshares

$35.31

-0.21 (-0.59%)

17:26
10/22/17
10/22
17:26
10/22/17
17:26
Conference/Events
Union Bankshares to host special shareholder meeting »

Special Shareholder…

XBKS

Xenith Bankshares

$32.74

-0.1 (-0.30%)

UBSH

Union Bankshares

$35.31

-0.21 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 15

    Nov

UBSH

Union Bankshares

$35.31

-0.21 (-0.59%)

, XBKS

Xenith Bankshares

$32.74

-0.1 (-0.30%)

17:23
10/22/17
10/22
17:23
10/22/17
17:23
Conference/Events
Xenith Bankshares to host special shareholder meeting »

Special Shareholder…

UBSH

Union Bankshares

$35.31

-0.21 (-0.59%)

XBKS

Xenith Bankshares

$32.74

-0.1 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ROKA

Roka Bioscience

$1.53

-0.24 (-13.56%)

17:20
10/22/17
10/22
17:20
10/22/17
17:20
Conference/Events
Roka Bioscience to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCFC

OceanFirst Financial

$28.01

0.19 (0.68%)

17:03
10/22/17
10/22
17:03
10/22/17
17:03
Conference/Events
OceanFirst Financial to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 15

    Nov

OCFC

OceanFirst Financial

$28.01

0.19 (0.68%)

, SNBC

Sun Bancorp

$25.60

0.05 (0.20%)

16:57
10/22/17
10/22
16:57
10/22/17
16:57
Conference/Events
Sun Bancorp to host special shareholder meeting »

Special Shareholder…

OCFC

OceanFirst Financial

$28.01

0.19 (0.68%)

SNBC

Sun Bancorp

$25.60

0.05 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 27

    Oct

  • 15

    Nov

SGU

Star Gas Partners, L.P.

$10.52

-0.16 (-1.50%)

16:49
10/22/17
10/22
16:49
10/22/17
16:49
Conference/Events
Star Gas Partners, L.P. to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ETRM

EnteroMedics

$2.05

0.07 (3.54%)

16:44
10/22/17
10/22
16:44
10/22/17
16:44
Conference/Events
EnteroMedics to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PSTB

Park Sterling Bank

$12.84

-0.02 (-0.16%)

, SSB

South State

$92.15

-0.2 (-0.22%)

16:39
10/22/17
10/22
16:39
10/22/17
16:39
Conference/Events
South State to host special shareholder meeting »

Special Shareholder…

PSTB

Park Sterling Bank

$12.84

-0.02 (-0.16%)

SSB

South State

$92.15

-0.2 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

SSB

South State

$92.15

-0.2 (-0.22%)

, PSTB

Park Sterling Bank

$12.84

-0.02 (-0.16%)

16:36
10/22/17
10/22
16:36
10/22/17
16:36
Conference/Events
Park Sterling Bank to host special shareholder meeting »

Special Shareholder…

SSB

South State

$92.15

-0.2 (-0.22%)

PSTB

Park Sterling Bank

$12.84

-0.02 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FSBK

First South Bancorp

$18.66

0.14 (0.76%)

, CARO

Carolina Financial

$36.17

0.23 (0.64%)

16:22
10/22/17
10/22
16:22
10/22/17
16:22
Conference/Events
Carolina Financial to host special shareholder meeting »

Special Shareholder…

FSBK

First South Bancorp

$18.66

0.14 (0.76%)

CARO

Carolina Financial

$36.17

0.23 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

CARO

Carolina Financial

$36.17

0.23 (0.64%)

, FSBK

First South Bancorp

$18.66

0.14 (0.76%)

16:19
10/22/17
10/22
16:19
10/22/17
16:19
Conference/Events
First South Bancorp to host special shareholder meeting »

Special Shareholder…

CARO

Carolina Financial

$36.17

0.23 (0.64%)

FSBK

First South Bancorp

$18.66

0.14 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

FOXA

21st Century Fox

$27.50

0.13 (0.47%)

13:41
10/22/17
10/22
13:41
10/22/17
13:41
Periodicals
Fox knew of new harassment settlement before signing O'Reilly, Reuters says »

Forced to resign in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

TM

Toyota

$123.71

0.64 (0.52%)

13:37
10/22/17
10/22
13:37
10/22/17
13:37
Periodicals
Toyota to halt operations at Japan plants as typhoon approaches, Reuters says »

Toyota is suspending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICE

IntercontinentalExchange

$66.12

-0.73 (-1.09%)

, BAC

Bank of America

$27.17

0.59 (2.22%)

13:34
10/22/17
10/22
13:34
10/22/17
13:34
Hot Stocks
IntercontinentalExchange completes BofA Merrill's Index Platform acquisition »

Intercontinental Exchange…

ICE

IntercontinentalExchange

$66.12

-0.73 (-1.09%)

BAC

Bank of America

$27.17

0.59 (2.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 02

    Nov

VCYT

Veracyte

$9.30

0.11 (1.20%)

13:30
10/22/17
10/22
13:30
10/22/17
13:30
Hot Stocks
Veracyte announces new data, highlights Afirma GSC performance »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.88

0.13 (0.20%)

13:19
10/22/17
10/22
13:19
10/22/17
13:19
Hot Stocks
Study shows Merck Zepatier resulted in high sustained virologic response rates »

Merck has announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

  • 30

    Nov

  • 02

    Feb

EADSY

Airbus

$23.76

-0.135 (-0.56%)

, BDRBF

Bombardier

$2.25

0.04 (1.81%)

12:57
10/22/17
10/22
12:57
10/22/17
12:57
Periodicals
Airbus turmoil overshadows bid to rescue Bombardier CSeries, Reuters says »

Airbus's (EADSY)…

EADSY

Airbus

$23.76

-0.135 (-0.56%)

BDRBF

Bombardier

$2.25

0.04 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$257.11

1.32 (0.52%)

, SPX

S&P 500

11:19
10/22/17
10/22
11:19
10/22/17
11:19
Periodicals
Senate Republican Leader says tax bill to be revenue neutral, Reuters reports »

Mitch McConnell said he…

SPY

SPDR S&P 500 ETF Trust

$257.11

1.32 (0.52%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$15.56

0.31 (2.03%)

11:15
10/22/17
10/22
11:15
10/22/17
11:15
Periodicals
People use Snapchat at parties, not as much at sports stadiums, Recode says »

There seems to be a huge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

  • 08

    Nov

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.